<DOC>
	<DOCNO>NCT02437539</DOCNO>
	<brief_summary>The primary objective study test new radiotracer call 68Ga-NOTA-AE105 PET image uPAR ( urokinase plasminogen activator receptor ) . The tracer potential identifying invasive cancer phenotype , thereby distinguish aggressive less aggressive tumor . This first human study test radiotracer cancer patient . The biodistribution tumor uptake evaluate repeated PET imaging ( 10 minute , 1 hour 2 hour post injection ) .</brief_summary>
	<brief_title>Evaluation New Radiotracer ( 68Ga-NOTA-AE105 ) Diagnosing Aggressive Cancer With Positron Emission Tomography</brief_title>
	<detailed_description>The primary objective study test new radiotracer call 68Ga-NOTA-AE105 PET image uPAR ( urokinase plasminogen activator receptor ) . The tracer potential identifying invasive cancer phenotype , thereby distinguish aggressive less aggressive tumor . This first human study test radiotracer cancer patient . The biodistribution tumor uptake evaluate repeated PET scan ( 10 minute , 1 2 hour post injection ) . The primary end point safety , biodistribution dosimetry 68Ga-NOTA-AE105 . In addition , quantitative uptake 68Ga-NOTA-AE105 compare expression uPAR measure directly tumor tissue obtain surgery biopsy . The project monitor evaluated accordance principle Good Clinical Practice ( GCP ) .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1. diagnosed cancer prostate , breast urinary bladder 2. capable understand give full inform consent 1. pregnancy 2. lactation 3. contraindication use intravenous CT contrastagencies 4. claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>